This webinar takes place on Wednesday October 2nd between 16.00 and 16.30 CEST / 15.00-15.30 BST / 10.00-10.30 AM EDT / 7.00-7.30 AM PDT.

Follow the link to register for the webinar. Please note that the presentation will be given during the live event only and on demand viewing at a later date will not be possible. Contact us for any questions.

 

REGISTER FOR LIVE WEBINAR

 

THIS WEBINAR IS ARRANGED BY CELLECTRICON AB. FOR MORE INFORMATION ON THE HANDLING OF YOUR PERSONAL INFORMATION, SEE OUR PRIVACY POLICY.

Abstract:

Peripheral neuropathies, such as chronic pain, affect numerous people and treatment options are still limited. Patients with peripheral neuropathy suffer from abnormal signal transduction between the peripheral and the central nervous system.

In this webinar, we will present different high-capacity in vitro models for the assessment of pain-related mechanisms. We will cover the application of a microfluidic co-culture platform that enables exploration of the signal transduction between the peripheral and central nervous system. By parallelizing up to 96 experiments at a time, this platform provides much-needed capacity for efficient drug discovery. Moreover, we will present a study where lentiviral knock-down was combined with high-capacity electrophysiology to functionally validate pain targets. Together, these examples showcase how high-capacity in vitro models can be a valuable tool to assess mechanisms and confirm targets involved in peripheral neuropathies.

Presented by:

Lydia Moll, External Collaborations Manager

Lydia joined the company in 2019 when she started her industrial PhD in Medical Sciences at Karolinska Institutet, Sweden, in collaboration with Cellectricon. Her PhD project was part of BonePain II, a European Innovative Training Network committed to promote research, innovation and education within bone pain. Lydia’s research was focused on the development of high-capacity in vitro assays for chronic pain research. As part of her thesis work, she developed neuronal co-culture models on a microfluidic platform. Lydia is now an External Collaborations Manager at Cellectricon where she designs and drives drug discovery projects for clients active in the area of peripheral neuropathies.